University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Vadim Koshkin, MD

Vadim Koshkin, MD

Assistant Professor, Division of Hematology and Oncology, Department of Medicine, UCSF

Cancer Center Program Memberships

Cancer Immunology

Research Summary

I am a genitourinary medical oncologist and in this capacity I specialize in caring for patients with bladder, prostate, kidney and testicular cancers. My focus is in clinical and translational research in bladder and prostate cancers, in particular the design and implementation of clinical trials for patients with these malignancies and the discovery and validation of novel biomarkers and treatment targets.

Education

  • University of Pennsylvania, Philadelphia, PA, BA, 05/2007, Cognitive Science
  • University of Chicago, Chicago, IL, MD, 06/2012, Medicine
  • University of Michigan Health System, Ann Arbor, MI, Intern, 06/2013, Internal Medicine
  • University of Michigan Health System, Ann Arbor, MI, Resident, 06/2015, Internal Medicine
  • Cleveland Clinic, Cleveland, OH, Fellow, 06/2018, Hematology-Oncology

Professional Experience

  • 2018-Present
    Assistant Professor, Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA
  • 2015-2018
    Fellow, Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
  • 2013-2015
    Resident Physician, Internal Medicine, University of Michigan Health System, Ann Arbor, MI
  • 2012-2013
    Intern, Internal Medicine, University of Michigan Health System, Ann Arbor, MI

Honors & Awards

  • 2017
    John Quale Travel Fellowship Award, BCAN Bladder Cancer Think Tank
  • 2017
    Young Investigator Abstract Award, International Kidney Cancer Symposium
  • 2017
    Conquer Cancer Foundation Merit Award, ASCO 2017 Annual Meeting
  • 2016
    AACR/ASCO Methods in Clinical Cancer Research Workshop Participant
  • 2017
    Accelerating Anticancer Agent Development & Validation Workshop Participant
  • 2016
    FDA-ASCO: Hematology and Oncology Fellows Day Workshop Participant
  • 2015
    ASCO 2015 Annual Meeting Merit Award
  • 2011
    Teaching Assistant for Clinical Pathophysiology and Therapeutics (top 20% of med school class)
  • 2009, 2012
    Keith Edson Scholarship for International Medicine Experience
  • 2009
    Certificate of Merit Award for education exhibit at RSNA annual meeting
  • 2008-2012
    Jewish Federation of Metropolitan Chicago Academic Scholarship
  • 2007
    Best Senior Thesis in Cognitive Science, College Alumni Society Award
  • 2004, 2006, 2007
    Dean's List, University of Pennsylvania, College of Arts and Sciences
  • 2003-2007
    George M. Pullman Foundation Academic Scholarship

Selected Publications

  1. Koshkin VS, Mir MC, Barata P, Gul A, Gupta R, Stephenson AJ, Kaouk J, Berglund R, Magi-Galluzzi C, Klein EA, Dreicer R, Garcia JA. Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. Invest New Drugs. 2019 Jun; 37(3):559-566.
    View on PubMed
  2. Koshkin VS, O’Donnell P, Yu EY, Grivas P. Systematic Review: Targeting HER2 in Bladder Cancer. Bladder Cancer. 2019; 5(1):1-12.
    View on PubMed
  3. Koshkin VS, Basu A, Grivas P. Translational Cancer Research. The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape. 2018.
    View on PubMed
  4. Koshkin VS, Small EJ. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018 Dec; 10(12):445-454.
    View on PubMed
  5. Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res. 2019 Jan 01; 25(1):210-221.
    View on PubMed
  6. Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, Koshkin V, Ornstein M, Gilligan TD, Wood LS, Rini BI, Angelov L, Garcia JA. Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):413-419.e1.
    View on PubMed
  7. Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, Grivas P, Rini B, Garcia J, Auchus RJ, Sharifi N. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. J Clin Invest. 2018 Aug 01; 128(8):3333-3340.
    View on PubMed
  8. Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. Prostate. 2018 Sep; 78(13):1035-1041.
    View on PubMed
  9. Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag. 2018; 14:1019-1040.
    View on PubMed
  10. Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P. Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. Target Oncol. 2018 Jun; 13(3):353-361.
    View on PubMed
  11. Koshkin VS, Grivas P. Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. Transl Androl Urol. 2018 Jun; 7(3):504-507.
    View on PubMed
  12. Koshkin VS, Grivas P. Targeted Oncology. Future Directions of Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer. 2018.
    View on PubMed
  13. Koshkin VS, Grivas P. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. Curr Oncol Rep. 2018 04 11; 20(6):48.
    View on PubMed
  14. Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clin Genitourin Cancer. 2018 08; 16(4):e879-e892.
    View on PubMed
  15. Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018 Jan 29; 6(1):9.
    View on PubMed
  16. Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, Rini B, Grivas P. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. Clin Genitourin Cancer. 2018 04; 16(2):e437-e442.
    View on PubMed
  17. Barata PC, Koshkin VS, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J, Rini B, Grivas P. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017 Oct 01; 28(10):2458-2463.
    View on PubMed
  18. Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus. 2019 Mar; 5(2):242-249.
    View on PubMed
  19. Grivas P, Koshkin VS, Pal SK. Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma? Ann Oncol. 2017 04 01; 28(4):680-682.
    View on PubMed
  20. Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH. Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. J Clin Oncol. 2016 Oct 20; 34(30):3680-3685.
    View on PubMed

Go to UCSF Profiles, powered by CTSI